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To develop and validate a rapid, specific and highly sensitive method to quantify nimodipine in human 
plasma using dibucaine as the internal standard (IS). The analyte and IS were extracted from plasma 
samples by liquid-liquid extraction using hexane-ethyl acetate (1:1 v/v). The chromatographic separation 
was performed on a Varian® Polaris C18 analytical column (3 mm, 50 x 2.0 mm) and pre-column 
SecurityguardTM C18 (4.0 x 3.0 mm) with a mobile phase of Acetonitrile-Ammonium acetate 0.02 ml/L 
(80:20v/v). The method had a chromatographic run time of 4.5 min and linear calibration curve over the 
range of 0.1- 40 ng/mL (r > 0.9938). The limit of quantification was 100 pg/mL. Acceptable precision 
and accuracy were obtained for concentrations over the standard curve ranges. This validated method 
was successfully applied in determining the pharmacokinetic profile of nimodipine tablets of 30 mg 
administered to 24 healthy volunteers. The proposed method of analysis provided a sensitive and specific 
assay for nimodipine determination in human plasma. The time for the determination of one plasma 
sample was 4.5 min. This method is suitable for the analysis of nimodipine in human plasma samples 
collected for pharmacokinetic, bioavailability or bioequivalence studies in humans.
Uniterms: Nimodipine/determination in plasma. Nimodipine/pharmacokinetic profile. Nimodipine/
quantitative analysis. Pharmacokinetics/method validation.
Um método rápido, específico e sensível para quantificar nimodipino em plasma humano usando 
dibucaína como padrão interno (IS) é descrito. O analito e o IS foram extraídos das amostras de plasma 
por extração líquido-líquido usando hexano-acetato de etila (1:1 v/v). A separação cromatográfica foi 
realizada utilizando-se uma coluna analítica C18 Varian® Polaris (3 mm, 50 x 2,0 mm) e uma pré-coluna 
SecurityguardTM C18 (4,0 x 3,0 mm) e acetonitrila-acetato de amônia 0,02 mol/L (80:20 v/v) como 
fase móvel. O método apresentou tempo total de corrida de 4,5 min e curva de calibração linear com 
concentrações entre 0,1-40 ng/mL (r > 0,9938). O limite de quantificação foi de 100 pg/mL. Os valores 
de precisão e exatidão foram obtidos por meio da análise das amostras de controle de qualidade. A análise 
de uma única amostra de plasma foi realizada em 4,5 minutos. A metodologia validada foi aplicada 
na determinação do perfil farmacocinético do nimodipino, comprimido de 30 mg administrado em 24 
voluntários saudáveis. O método para quantificar nimodipino em plasma é adequado para aplicação em 
estudos farmacocinéticos, biodisponibilidade e bioequivalência em humanos.
Unitermos: Nimodipino/determinação em plasma. Nimodipino/perfil farmacocinético. Nimodipino/
análise quantitativa. Farmacocinética/validação de método.
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INTRODUCTION
Nimodipine (Figure 1) is a dihydropyridine cal-
cium channel blocker known for its preferential action 
on cerebral blood vessels (Kazda, Toward, 1982; Haws 
et al., 1983), but it is currently used to prevent and treat 
the ischemic damage caused by cerebral arterial spasm 
in subarachnoid hemorrhage (Dorhout Mees et al., 2007; 
Stachura et al., 2002). Nimodipine has also been used in 
the treatment of ischemic stroke (Svetyi et al., 2002; So-
brado et al., 2003; Fogelholm et al., 2004), multi-infarct 
dementia (Fischhof et al., 1989; Pantoni et al., 2000) and 
migraine prophylaxis (Evers, 1999; Victor, Ryan, 2003). 
Several analytical techniques have been applied in 
the quantification of nimodipine in biological matrices. 
Gas chromatography (GC) methods with electron-capture 
(Krol et al., 1984; Jackobsen, et al., 1986) and nitrogen-
phosphorus detection (Rosseel, Bogaert, Huyghens, 1990) 
were used to determine nimodipine in plasma, which can 
provide a lower limit of quantification (LLOQ) of 5 ng/mL, 
using 1 mL of plasma. The method described by Krol et 
al. (1984) is sensitive and selective; however, it requires a 
large amount of plasma and elaborate and lengthy sample 
preparation. 
HPLC with UV detection (Qian, Gallo, 1992; Aymard 
et al., 1998) and electrochemical detection (López et al., 
2000) has a sensitivity of about 1 ng/mL, using 1 mL of 
plasma, but these methods are time-consuming (more than 
10 min). In all the reported methods above, plasma volume 
requirement was high, chromatographic run time was longer 
and sensitivity was inadequate for pharmacokinetic studies. 
The relatively longer run time for nimodipine registered by 
these analytical methods are not adequate for the analysis 
of a high number of samples. Fischer et al., 1993 developed 
a GC-MS method combined with chiral stationary phase 
HPLC for the separation and determination of nimodipine 
enantiomers, which had an LLOQ of 0.1 ng/mL, using 
0.5 mL of plasma. However, the analytical time was more 
than 30 min, which is not suitable for the analysis of a large 
number of biological samples. 
The usefulness of liquid chromatography/tandem 
mass spectrometry (LC-MS/MS) has been demonstrated 
for a wide range of applications in the bioanalytical, 
environmental and pharmaceutical fields (Jemal, 2000; 
Cech, Enke, 2001; Niessen, 2003). This powerful se-
paration and detection technique is widely used for the 
determination of drugs in biological fluids. Mück (1995) 
developed an LC-MS-MS method providing an LLOQ 
of 0.5 ng/mL, using a 1 mL plasma sample. This method 
was used for the quantification of nimodipine enantio-
mers. Gualano et al. (1999) and Qiu et al. (2004) reported 
an LC-MS/MS method with an atmospheric pressure 
chemical ionization (APCI) source in selected reaction 
monitoring mode for the determination of nimodipine in 
human plasma with an LLOQ of 0.25 and 0.24 ng/mL, 
respectively. 
Nirogi et al. (2006) developed an LC-MS-MS me-
thod to determine nimodipine in human plasma which had 
an LLOQ of 200 pg/mL using 0.5mL plasma. Recently, 
Qin et al. (2008) published a method for quantification 
of nimodipine in human plasma using ultra performance 
liquid chromatography–tandem mass spectrometry. The 
validated method attained a limit of quantification of 
0.2ng/mL using 500 µL plasma. In these methods, nimo-
dipine concentrations were not always detectable in the 
small plasma samples used (0.5–1 mL). This fact made 
them unsuitable for time-course analysis in cases where 
only small plasma volumes are available (pharmacokinetic 
studies in experimental animals or children). 
LC-MS/MS is one of the most common techniques 
employed for the quantification of drugs in biological ma-
trices, due to its higher levels of specificity and sensitivity. 
Thus, the present report describes the development and 
validation of an LC-MS/MS method for the quantification 
of nimodipine with use of dibucaine as the internal standard 
(Figure 1) and the method’s clinical application in pharma-
cokinetic and bioavailability studies in human volunteers. 
MATERIAL AND METHODS
Reference compounds and chemicals
Nimodipine was purchased from ICN Biomedical 
(Ohio, USA) and dibucaine (IS) was purchased from 
USP Pharmacopeia (New York, NY, USA). Acetonitrile 
(ACN) was purchased from EM Science (Gibbstown, 
NJ, USA); methanol (MeOH), ethyl acetate, hexane and 
ammonium acetate were purchased from Merck (Rio 
de Janeiro, RJ, Brazil). The ACN and MeOH used were 
HPLC grade solvents. All other reagents were analytical 
grade. A Milli-Q® (Millipore, Mosheim, France) water 
FIGURE 1 - Chemical structures of nimodipine (A) and 
dibucaine (B, internal standard).
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purification system was used to obtain the purified water 
for the HPLC analysis. 
Preparation of standard solutions and reagents
A stock solution of nimodipine 100 mg/mL was pre-
pared in ACN. Working standard solutions were prepared 
from the stock solution by dilution with ACN to produce 
a final concentration of 10 mg/mL.
A stock solution of dibucaine 100 mg/mL (Figure 1) 
was prepared in MeOH. Working standard solutions were 
prepared from the stock solution by dilution with MeOH 
to produce a final concentration of 50 ng/mL.
Calibration curves
Calibration standards were prepared by spiking 
control human plasma with standard solutions containing 
nimodipine to give standards of 0.1, 0.5, 2.0, 10, 25 and 
40 ng/mL. A fixed concentration of dibucaine was added to 
all assay tubes as an internal standard. Zero concentration 
plasma samples used in each run were prepared containing 
internal standard only. In each run, a plasma blank sample 
(no IS) was also analyzed.
Quality control samples
Quality control (QC) samples were prepared at three 
different levels: low level (LQC), three times the lower 
limit of quantification (LLOQ); middle level (MQC), 
approximately midway between low quality control and 
high quality control; and high level (HQC), 75-90% of the 
upper limit of the quantification (ULOQ). Quality control 
samples were prepared by spiking different samples of 
human plasma with 0.3, 15 and 35 ng/mL of nimodipine. 
Sample extraction procedure
To prevent the photodegradation of nimodipine, the 
whole experiment including plasma collecting, sample 
preparation and instrumental analyses were performed 
under feeble yellow light.
A total of 300 mL of plasma were extracted from the 
appropriate tube after adding 25 mL of internal standard 
dibucaine (50 ng/mL). The tubes were vortex-mixed for 
1 min. A volume of 1000 mL of hexane/ethyl acetate (1:1 
v/v) was then added, and the samples were vortex-mixed 
for 5 min. The tubes were centrifuged at 2000 g for 5 min 
at 37 ºC. The upper organic layer (800 mL) was carefully 
removed, transferred to new tubes, and evaporated to dry-
ness with a gentle stream of nitrogen in a dry bath at 37 ºC.
A 150-mL aliquot of ACN was added to tubes which 
were then vortex-mixed for 1 min to reconstitute the resi-
due. The solutions were transferred to microvials which 
were capped and placed in an autosampler rack. Aliquots 
of 10 mL were injected automatically into the liquid chro-
matography system. 
Mass spectrometry and chromatography 
conditions
The chromatographic runs were carried out using 
an HP/Quat Pump Series 1100 analytical pump and an 
HP/ALS Series 1100 auto sampler. The mobile phase 
involved a mixture of ACN-0.02 mol/L ammonium ace-
tate (80:20, v/v) pumped at a flow rate of 1.0 mL/min 
through the analytical column (Varian® Polaris C18 , 3 mm, 
50 x 2.0 mm) and pre-column (SecurityguardTM C18 , 
4.0 x 3.0 mm), at 20 ºC. A split of the column eluant of ap-
proximately 1:10 was included so that only approximately 
50 mL/min entered the mass spectrometer. The injection 
volume was 10 mL and the total run time was 4.5 min.
The mass spectrometer (micromass Quattro LC) 
equipped with an electrospray source using a crossflow 
counter electrode was run in positive mode (ES+), and set 
up in multiple reaction monitoring (MRM), monitoring the 
transitions 418.6>342.6 and 344.2 >271.0 for nimodipine 
and dibucaine, respectively. The source and dessolvation 
temperature was 100 °C and 300 °C, respectively. The cone 
and dessolvation gas flow (N2) was 116 L/h and 533 L/h, 
respectively. The dwell time was set at 0.5 s, and the values 
of the capillary voltage, the cone energy and collision energy 
were 4.2 KV, 15 V, 10 eV for nimodipine and 4.2 KV, 20 V 
and 21 eV for dibucaine, with a gas pressure (argon) of 
2.5 x 10-3 mbar. Data acquisition and analysis were perfor-
med using the software MassLynx (V 3.5, running under 
Windows NT (v 4.0) on a Pentium PC).
Method validation
Sample analysis was always carried out in a GLP-
compliant manner, and therefore, the LC-MS-MS methods 
needed to be validated according to currently accepted 
Food and Drug Administration (FDA) and National Health 
Surveillance Agency (ANVISA) bioanalytical method 
validation guidelines (FDA, 2001; ANVISA, 2003). The 
following parameters were considered.
Linearity (ANVISA, 2003) was determined to assess 
the performance of the method. A linear least-squares 
regression with a weighting index of 1/x was performed 
on the peak areas of nimodipine and IS to nimodipine con-
centration ratios for the six plasma standards (0.1, 0.5, 2.0, 
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10, 25 and 40 ng/mL) in triplicate to generate a calibration 
curve. For the determination of linearity, standard calibra-
tion curves of at least six points (non-zero standards) were 
used. In addition, a blank and zero plasma samples were 
also analyzed to confirm the absence of interference; these 
two samples were not used to construct the calibration 
function. Four out of six non-zero standards, including 
LLOQ and ULOQ, had to meet the following acceptance 
criteria: no more than 20% deviation at LLOQ and no 
more than 15% deviation for standards above the LLOQ. 
The acceptance criterion for the correlation coefficient 
was 0.98 or higher (ANVISA, 2003) otherwise, the cali-
bration curve would be rejected. Five replicate analyses 
were performed.
The method’s selectivity was tested by screening six 
different batches of healthy human plasma. Each blank 
sample was tested for interference using the proposed 
extraction procedure and chromatography/mass spectro-
metry conditions, and compared with those obtained using 
an aqueous solution of the analyte at a concentration near 
the LLOQ.
The inter-day precision and accuracy was determi-
ned over three days by analyzing 45 QC samples (Hubert 
et al., 1999). The intra-day precision and accuracy of the 
assay was measured by analyzing five spiked samples of 
nimodipine at each QC level (0.3, 15 and 35 ng/mL). The 
acceptance criteria for precision and accuracy deviation 
required that values be within 15% of the actual values. 
The recoveries were calculated for both nimodipine 
and dibucaine by comparing peak areas of the extracted 
samples with the peak areas of unextracted pure authentic 
standard solutions at three QC levels.
For sensitivity determination, the lowest standard 
concentration in the calibration curve was considered as 
the limit of quantification, and had to meet the following 
criteria: LLOQ response should be five times the response 
of the blank and the LLOQ response should be identifiable, 
discrete and reproducible with a precision of 20% and 
accuracy of 80-120%. The 100 pg/mL concentration was 
investigated as the lower limit of quantification. Time-
dependent precision and accuracy were determined. 
Quality control samples were subjected to the follo-
wings stability tests: 
Short-term stability (autosampler stability) – Short-
term stability was determined by analyzing extracted 
QC samples kept under autosampler conditions for 10h. 
Samples were analyzed as mentioned above.
Freeze and thaw stability – QC plasma samples con-
taining nimodipine were tested after three freeze (-20 ºC) 
and thaw (room temperature) cycles.
Long-term stability – The long-term stability of 
nimodipine in human plasma was studied for a period of 
61 days employing QC samples at three different levels. 
Standard solution stability – The stability of stan-
dard solutions was evaluated by testing their validity for 
6 h at room temperature and after 7 days frozen at -20 ºC. 
Application of the method in a pharmacokinetic 
study in healthy volunteers
This method was applied in the analysis of plasma 
samples after the administration of a single dose of 30 mg 
nimodipine tablets to healthy volunteers participating in 
a bioequivalence study. The study was approved by the 
Federal University of Ceara Ethics Committee. The age 
of 24 volunteers of both sexes (12 males and 12 females) 
ranged from 20 to 40 years (mean ± SD; 25.4 ± 6.19), and 
subjects had a body mass index (BMI) ranging from 19.7 
to 27.6 kg/m2 (22.8 ± 2.17). All subjects gave their written 
informed consent, and the Ethics Committee of Federal 
University of Ceara approved the clinical protocol. The 
study was conducted in accordance with the provisions of 
the Declaration of Helsinki (1964), Tokyo (1975), Venice 
(1983), Hong Kong (1989), Somerset West (1996) and 
Edinburgh (2000) revisions.
The study had a single dose, two-way randomized 
crossover design with a seven days washout period betwe-
en doses. During each period, the volunteers were hospita-
lized at 09:00 p.m. and after an overnight fast period they 
received (at approximately 7:00 a.m.) a single dose of each 
nimodipine formulation with 200 mL of water. Two hours 
after drug administration, a light breakfast was provided 
and a standard lunch and dinner were consumed 5 and 11h 
after dosing, respectively. No other food was permitted 
during the “in-house” period, and liquid consumption 
was allowed ad libitum after lunch (with the exception 
of xanthine-containing drinks, including tea, coffee, and 
cola). Concomitant medication was not allowed. 
Blood samples (9 mL) from a suitable antecubital 
vein were collected into heparin-containing tubes before 
and, 0.167, 0.25, 0.333, 0.5, 0.667, 0.833, 1, 1.25, 1.5, 2, 
3, 4, 6, 8, 12, 16, 24, 36 and 48h after the administration 
of the nimodipine formulation. The blood samples were 
centrifuged at 2000 g for 10 min at room temperature and 
the plasma was removed and stored at -20ºC until assayed 
for its nimodipine content. All samples from a single vo-
lunteer were analyzed in the same run in order to avoid 
inter-assay variations.
Pharmacokinetic parameters were determined from 
the plasma concentration-time data. The first-order termi-
nal elimination rate constant (Ke) was estimated by linear 
regression from the points describing the elimination pha-
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se on a log-linear plot. The elimination half-life (t1/2) was 
derived from this rate constant (t1/2 = ln(2)/Ke) where t1/2 is 
the half-life time, ln(2) is the Neperian logarithm and Ke 
is the elimination rate constant. The maximum observed 
plasma concentration (Cmax) and the time taken to achieve 
this maximum level (Tmax) were obtained directly from the 
curves. The areas under the curve for nimodipine plasma 
concentration versus time for 0-48h (AUC0-48h) were cal-
culated by applying the linear trapezoidal method. The 
extrapolation of this area to infinity (AUC0-∞) was done by 
adding the value C48/Ke to the calculated AUC0-48 where 
C48 is the nimodipine plasma concentration at 48h and Ke 
is the first-order terminal elimination rate constant.
Bioequivalence (BE) between the reference and 
test formulations was assessed on the basis of maximum 
plasma concentration of nimodipine (Cmax) and area under 
the plasma concentration versus time curve from time 0 
to the last sampling time (AUC0–48h) by calculating the 
mean ratios and 90% confidence interval (CIs) on log-
transformed data. The inclusion of the 90% CIs for the 
ratios in the 80% to 125% bioequivalence interval, were 
analyzed using a parametric test (ANOVA). The variability 
between the groups (sequence), periods and formulations 
was evaluated using ANOVA test. The computer programs 
used to calculate the pharmacokinetic parameters (Cmax 
and AUC) and to carry out statistical analysis were Win-
NonlinTM, version 3.1 (Pharsight, Mountain View, CA); 
EquivTest, version 2.0 (Statistical Solution Ltd., Saugus, 
MA); and GraphPad Prim, version 2.0 (Software Inc., San 
Diego, CA).
RESULTS AND DISCUSSION
Method validation
Separation and specificity
LC-MS/MS method in multiple reaction monitoring 
(MRM) is a very powerful technique for pharmacokinetic 
studies since it provides sensitivity and selectivity require-
ments for analytical methods. Thus, the MRM technique 
was chosen for the assay development. The MRM state 
file parameters were optimized to maximize the response 
for the analyte.
Nimodipine and IS gave protonated precursor 
molecular ions [MH]+ in the MS mode. The major ions 
observed were m/z = 418.6 for nimodipine and m/z = 344.2 
for the IS. The most intense product ions observed in the 
MS/MS spectra were m/z = 342.6 for nimodipine and m/z 
= 271.0 for IS. 
Figure 2 (A) shows that, due to the high specificity 
of the MS/MS technique, no endogenous interfering pe-
FIGURE 2 - Representative MRM chromatograms: (A) a 
blank plasma sample; (B) a blank plasma sample spiked with 
nimodipine (15 ng/mL) and dibucaine (50 ng/mL); (C) a 
volunteer sample 0.5 h after oral administration of nimodipine 
(30 mg) in healthy volunteer; Peaks I and II refer to nimodipine 
and dibucaine.
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aks appeared at the retention times of the compounds of 
interest. Figure 2 (B) also shows that under the described 
chromatographic conditions, the retention times were 
2.28 min and 2.58 min for nimodipine and dibucaine, 
respectively. The total HPLC-MS-MS analysis time was 
4.5 min per sample.
Most reported methods require extensive sample 
work-up and laborious, time-consuming extraction pro-
cedures. Although many of these methods offer the ad-
vantage of being specific, they do require large volumes 
of plasma and/or are not economically feasible for routine 
use in most bioavailability, pharmacokinetic or bioequiva-
lence studies where only small volumes of serum/plasma 
may be obtained. 
The LC-MS-MS method described here provides 
the necessary level of linearity, accuracy and precision for 
routine analysis of nimodipine in plasma. In addition, the 
high selectivity of multiple reaction monitoring (MRM) 
for different compounds meant that a simple extraction 
procedure could be used with shorter analysis times.
The combination of HPLC with ESI-MS-MS leads 
to short retention times and yields both high selectivity and 
sensitivity. ESI is an ionization technique that produces 
high mass-to-charge [M + 1]+ precursor ions with minimal 
fragmentation of the analyte.
Linearity and lower limit of quantification
The linear regression of the peak area to concen-
trations ratios was fitted over the concentration range of 
0.10-40 ng/mL, and a typical equation of the calibration 
curve was as follows: Y = 0.0502682 X + 0.00630674 (r = 
0.993824), where Y is the peak area ratio of nimodipine to 
dibucaine, and X is the concentration of nimodipine, and r 
is the correlation linear coefficient. Results of six represen-
tative calibration curves for HPLC-MS-MS determination 
of nimodipine are given in Table I.
The present LC-MS-MS method offered an LLOQ 
of 100 pg/mL with a mean accuracy of 7.0% and a mean 
precision of 103.0% (n=5), which is more sensitive than 
or comparable to reported methods (Krol et al., 1984; Ja-
ckobsen et al., 1986; Rosseel Bogaert, Huyghens, 1990; 
Qian, Gallo, 1992; Aymard et al., 1998; López et al., 2000; 
Blardi et al., 2002; Mück, 1995; Qiu et al., 2004; Nirogi et 
al., 2006; Qin et al., 2008). Data for LLOQ are presented 
in Table II. With the present LLOQ of 100 pg/mL, the 
nimodipine concentration can be determined in plasma 
samples up to 48 h after a single oral dose of 30 mg nimo-
dipine, which is sufficiently sensitive to investigate the 
pharmacokinetic behavior of nimodipine, to establish the 
relationship between dose and pharmacological effect and 
to identify doses that produce toxic responses in humans.
The presented method is not entirely different from 
those described earlier (Gualano et al., 1999; Qiu et al., 
2004; Nirogi et al., 2006; Qin et al., 2008) but combines 
lower plasma volume (300 mL), short retention time (2.28 
min for nimodipine and 2.58 min for dibucaine), a simple 
extraction procedure, sensitivity (100 pg/mL), accuracy, 
precision and linearity.
Precision and accuracy
The intra-day and inter-day precision and accuracy 
of the assay were measured by analyzing five spiked 
samples of nimodipine at each QC level (0.3, 15 and 
35 ng/mL). The results for intra-day and inter-day pre-
cision and accuracy are summarized in Table II. These 
results were within the acceptance criteria for precision 
and accuracy which stipulate that the deviation of values 
should be within 15% of the actual values (Shah et al., 
2000; FDA, 2001; ANVISA, 2003).
Recovery
The mean extraction recovery of nimodipine, deter-
mined at three concentrations of the quality controls, were 
71.5 (CV 3.09%), 70.51 (CV 1.64%), 74.02% (CV 4.23%), 
respectively. The mean extraction recovery of dibucaine 
was found to be 84.06% (4.78%).
Several kinds of liquid-liquid extraction and solid 
phase extraction methods have been published for the 
extraction of nimodipine from plasma samples (Mück, 
Bode, 1994; López et al., 2000). The solid phase extraction 
is laborious and requires SPE cartridges, increasing the 
cost of the analysis. In this experiment, different liquid-
liquid extraction conditions were evaluated including 
different extraction solvents. Four organic extraction 
solvents (hexane/n-butyl alcohol hexane/isoamyl alcohol, 
diethyl ether/dichloromethane and hexane/ethyl acetate) 
were evaluated. Among the tested solvents, hexane/ethyl 
acetate gave the best recovery values for both the drug and 
internal standard.
Stability studies
Short-term stability indicated reliable stability 
behavior under the experimental conditions of the regular 
runs. Results are given below in Table III. The data that 
represent the stability of nimodipine plasma samples over 
three cycles of freezing and thawing are given in Table 
III. The results indicate that the analyte is stable in human 
plasma for three freeze-thaw cycles, when stored at –20 ºC 
and thawed to room temperature.
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TABLE I - Data of concentrations of nimodipine calibration standards and statistics for precision and accuracy from six representative 
calibration curves
Nominal Concentration 
(ng/mL)
Mean ± SD 
(ng/mL)
Precision 
(%)
Accuracy 
(%)
0.10 0.1 ± 0.01 10.0 100.0
0.50 0.5 ± 0.01 2.0 100.0
2.0 1.91 ± 0.04 2.18 95.33
10.0 9.3 ± 0.07 0.76 92.97
25.0 26.3 ± 1.17 4.46 105.20
40.0 42.48 ± 0.1 0.24 106.21
Equation of the calibration curve: Y = 0.0502682 X + 0.00630674 (r = 0.993824)
TABLE II - Analytical precision and accuracy of nimodipine determination in spiked plasma samples, and of the lower limit of 
quantification (n=5)
Intra-day LOQ LQC MQC HQC 
Nominal Concentration, ng/mL 0.1 0.3 15 35
Mean ± SD 0.1 ± 0.01 0.30 ± 0.03 16.36 ± 0.13 38.40 ± 0.53
Precision (%) 0.0 8.57 0.81 1.37
Accuracy (%) 110 100.67 109.09 109.72
Inter-day
Mean ± SD 0.103 ± 0.01 0.31 ± 0.02 15.99 ± 0.66 38.39 ± 1.29
Precision (%) 7.0 5.46 4.12 3.37
Accuracy (%) 103 102.89 106.60 109.69
Table III summarizes the long-term stability data of 
nimodipine in plasma samples stored for a period of 61 
days at –20 ºC. The stability study of nimodipine in human 
plasma showed good stability behavior as the mean values 
of the tested samples were within the acceptance criteria of 
±15% of the initial values of the controls. These findings 
indicate that the storage of nimodipine plasma samples 
at –20 ºC is adequate for up to 61 days, and no stability-
related problems would be expected during the routine 
analysis of samples for pharmacokinetic, bioavailability 
or bioequivalence studies. 
The stability of working solutions was tested and es-
tablished at room temperature for 6h. Based on the results 
obtained, working solutions were prepared freshly just 
spiking samples for the calibration curve and the QC’s. 
The results revealed optimum stability for the prepared 
working solutions throughout the period intended for 
their daily use. 
Pharmacokinetic study
Nimodipine was well tolerated at the doses adminis-
tered and no significant adverse reactions were observed 
or reported. No biochemical parameters presented any 
clinically relevant alterations. There were no drop-outs, 
and all volunteers who started the study continued to the 
end and were discharged in good health.
The method was applied to determine the plasma 
concentration of nimodipine following a single oral ad-
ministration (30 mg) to 24 healthy volunteers. The mean 
(SD) concentration-time profiles for the two brands of 
nimodipine tablets are shown in Figure 3. 
The pharmacokinetic parameters for both formula-
tions are shown in Table IV. Mean peak plasma concen-
tration of nimodipine was reached at 9.47 ng/mL (test 
formulation) and 18.76 ng/mL (reference formulation) at 
2.34 and 0.98 h, respectively, after a single oral dose and 
then levels declined and remained detectable up to 48 h. 
The extent of absorption is a key characteristic of drug 
formulation, and therefore, AUC is an important parame-
ter for comparative bioavailability studies (FDA, 2001). 
However, two other parameters, Cmax and Tmax, are also 
important features of the therapeutic use of a drug (Chow, 
Liu, 2000) and hence were also considered in this study.
The statistical comparison of AUC0-48h and Cmax cle-
arly indicated a significant difference in the two brands of 
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TABLE III - Short-term stability, freeze-thaw stability, standard solution stability and long-term stability tests of nimodipine in 
human plasma at different QC levels
Short-term stability test (values in ng/mL)
Reference 
values: Low 
sample
Values after 10 h Reference 
values: Middle 
sample
Values after 10 h Reference 
values: High 
sample
Values after 10 h
Mean 0.33 0.32 16.85 16.42 39.15 37.49
Precision (%) 0.0 5.41 0.46 1.07 0.46 0.97
Accuracy (%) 110.0 106.66 112.33 109.48 111.85 107.11
Freeze-thaw stability test (values in ng/mL)
Reference 
values: Low 
sample
Values after 
3 cycles
Reference 
values: Middle 
sample
Values after 
3 cycles
Reference 
values: High 
sample
Values after 
3 cycles
Mean 0.32 0.32 16.60 16.49 37.98 39.15
Precision (%) 0.01 0.01 0.21 0.18 1.02 0.33
Accuracy (%) 108.0 106.89 110.69 109.94 108.5 111.86
Standard solution stability test - 6 h room temperature (values in ng/mL)
Reference 
values: Low 
sample
Values after 6 h Reference 
values: Middle 
sample
Values after 6 h Reference 
values: High 
sample
Values after 6 h
Mean 0.32 0.33 16.60 16.57 37.98 39.53
Precision (%) 2.76 3.50 1.28 2.06 2.70 1.08
Accuracy (%) 108.0 108.67 110.69 110.45 108.5 112.95
Standard solution stability test - 7 days frozen at -20 ºC (values in ng/mL)
Reference 
values: Low 
sample
Values after 
7 days
Reference 
values: Middle 
sample
Values after 
7 days
Reference 
values: High 
sample
Values after 
7 days
Mean 0.32 0.29 16.60 14.60 37.98 33.87
Precision (%) 2.76 2.44 1.28 1.48 2.70 1.0
Accuracy (%) 108.0 96.67 110.69 97.39 108.5 96.78
Long-term stability test (values in ng/mL)
Reference 
values: Low 
sample
Values after 
61 days
Reference 
values: Middle 
sample
Values after 
61 days
Reference 
values: High 
sample
Values after 
61 days
Mean 0.28 0.27 14.80 16.08 35.32 37.63
Precision (%) 1.59 3.26 1.11 3.36 1.14 1.97
Accuracy (%) 94.0 91.33 98.65 107.17 100.9 107.51
nimodipine tablets. The two brands of nimodipine were 
not bioequivalent (Table V). In Table VI, the results for 
Tmax demonstrated that there was a difference between the 
mean Tmax of the test formulation and the mean Tmax of the 
reference formulation (p = 0.02), with a 90% confidence 
interval.
The variability of the data studied (Tables VII and 
VIII) shows that for both Cmax and AUC0-48h the effect of se-
quence is not significant (P = 0.1188 for Cmax and P = 0.7829 
for AUC0-48h). In addition, it was observed that the effect of 
period is significant (P = 0.0164) for Cmax, but insignificant 
for AUC0-48h (P = 0.2226). One possible cause for the period 
effect is the washout. In this case all the volunteers respec-
ted the correct washout period, more than seven half-lives 
(ANVISA, 2006). In a crossover study, the washout period 
is the time necessary for the drug received in the first phase 
of the study to have been completely metabolized and/or 
eliminated from the body before starting the second study 
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FIGURE 3 - Mean plasma nimodipine concentration versus time profile obtained after a single oral administration of 30 mg 
nimodipine in tablet formulations.
TABLE IV - Descriptive statistics of the pharmacokinetic parameters of nimodipine 30mg from reference and test formulation
AUC0-∞ (ng*h/mL) AUC0-48h (ng*h/mL) Cmax (ng/mL) Tmax (h) t1/2 (h)
R T R T R T R T R T
Mean 71.62 73.18 57.22 60.66 18.76 9.47 0.98 2.34 32.78 27.83
Geometric Mean 69.44 70.03 54.22 60.27 15.04 8.38 0.78 1.86 29.51 25.04
SD 16.88 23.82 17.76 25.38 10.57 5.80 0.94 1.58 15.58 12.23
Minimum 39.37 41.97 27.49 32.81 3.57 3.77 0.32 0.66 14.52 7.5
Maximum 97.84 147.15 89.66 144.11 34.62 33.51 4 6 71.5 65.36
Median 73.51 67.86 58.03 54.73 19.96 8.42 0.75 2.00 28.33 27.03
CV (%) 95.46 56.33 47.52 31.04 23.57 67.56 61.27 43.94 41.83 32.54
AUC0-∞ = area under curve for drug concentration versus time from 0 (zero) extrapolated to infinity; AUC0-tlast = area under the 
curve for drug concentration versus time from time zero to the time of the last concentration greater than the limit quantification; 
Cmax = maximum plasma concentration; SD = standard deviation; t1/2 = plasma elimination half-life; Tmax = time to reach maximum 
concentration.; T = test formulation; R = reference formulation.
TABLE V - Average Bioequivalence Analysis Results for Test/Reference Ratios after Log Transformation for AUC0-48h and Cmax 
Parameters
Test/Reference Geometric Mean 90% 
CI
90% CI Power to test Percent intra-subject 
CV%
Cmax 55.73 (44.73-69.42) 23.79 46.59
AUC0-48h 104.56 (94.80-115.32) 87.96 19.94
AUC0-tlast = area under the curve for drug concentration versus time, from time zero to the time of the last concentration greater 
than the quantification limit; Cmax = maximum plasma concentration.
TABLE VI - Analysis of the individual difference of Tmax (test – reference)
Difference of Tmax (test – reference) 90% CI p-value
1.36 (0.71;2.00) 0.002
Tmax = time to reach maximum concentration; 90% CI= 90% Confidence interval.
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period, i.e. this time must be sufficiently long that no resi-
due is found from one treatment to another. The presence 
of residual effects influences the statistical inference of 
bioequivalence between the formulations (ANVISA, 2002).
The observed pharmacokinetics differences can 
be explained by possible variations in pharmaceutical 
development during the formulation process, such as the 
use of different raw materials or distinct amounts of the 
excipients, size of the particle or the crystalline form of 
excipient, lipid-soluble or water-soluble, and hydration, 
among others (Ansel, Popovich, Allen Jr, 2000). 
According to the literature, the t1/2 of nimodipine is 
approximately 8-9h but the initial decline in plasma con-
centration occurs faster, equivalent to a half-life of 1 to 3h. 
(Yan, Ding, Liu, 1993; Lian-Quing, Heng-Shan, Gang, 
1993; Dollery, 1999; Blardi et al., 2002; Qiu et al., 2004; 
Zhonggui et al., 2004; Hernandez-Hernandez et al., 2002). 
Previous studies showed these data, but sampling was con-
cluded between 5 and 10h after dosing, thereby possibly 
missing a longer elimination phase. Our results demons-
trated, however, that the mean half-life of nimodipine for 
the two formulations tested was 27.83 h (test formulation) 
and 32.78 h (reference formulation). Such a discrepancy 
could be due to the greater sensitivity of our method, with a 
limit of quantification of 100 pg/mL, while values found in 
previous studies were in the range 0.24 to 5 ng/mL (Krol et 
al., 1984; Jackobsen et al., 1986; Rosseel et al., 1990; Qian, 
Gallo, 1992; Fischer et al., 1993; Yan et al., 1993; Mück, 
1995; Aymard et al., 1998; Gualano et al., 1999; López et 
al., 2000; Blardi et al., 2002; Qiu et al., 2004; Zhonggui et 
al., 2004; Nirogi et al., 2006). This improved sensitivity 
enabled the determination of plasma drug concentrations up 
to 48 h after drug administration, which was not possible in 
other studies that allowed the measurement of plasma drug 
levels only up to 10 h after drug administration. 
CONCLUSION
The proposed method of analysis provided a sensi-
tive and specific assay for nimodipine determination in 
human plasma. The determination of one plasma sample 
needed only 4.5 min and more than 320 samples could be 
assayed daily, including sample preparation, data acquisi-
tion and processing stages. The method proved superior 
in sensitivity and speed to other reported methods. It 
was shown that this method is suitable for the analysis 
TABLE VII - Result of analysis of variance (ANOVA) to assess the effects of sequence and period for Cmax, log transformed, after 
administration of the test and reference formulations to 24 healthy volunteers
Source Degrees of freedom Sum of Squares Mean Square F P
Inter-Individual
Sequence 1 1.3058 1.3058 2.6333 0.1188
Residues (inter) 22 10.9093 0.4958 2.5235 0.0174
Intra-Individual
Drug 1 4.1027 4.1027 20.8794 0.0001
Period 1 1.3241 1.3241 6.7386 0.0164
Residues (intra) 22 4.3229 0.1964
Total 47 21.9649
TABLE VIII - Result of analysis of variance (ANOVA) to assess the effects of sequence and period for AUC0-48h, log transformed, 
after administration of the test and reference formulations to 24 healthy volunteers
Source Degrees of freedom Sum of Squares Mean Square F P
Inter-Individual
Sequence 1 0.0168 0.0168 0.0777 0.7829
Residues (inter) 22 4.7590 0.2163 5.5403 8.391E-05
Intra-Individual
Drug 1 0.0238 0.0238 0.6113 0.4426
Period 1 0.0614 0.0614 1.5747 0.2226
Residues (intra) 22 0.8589 0.0390
Total 47 5.7201
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of nimodipine in human plasma samples collected for 
pharmacokinetic, bioavailability or bioequivalence stu-
dies in humans.
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